Tags : Santhera

PharmaShots Weekly Snapshot (Oct 5-9, 2020)

Takeda Signs ~$1B Pact with Arrowhead for ARO-AAT Targeting Alpha-1 Antitrypsin-Associated Liver Disease    Published: Oct 9, 2020 | Tags: Alpha-1 Antitrypsin-Associated Liver Disease, Arrowhead, Collaborates, Commercialize. ARO-AAT, Develop, Takeda, with Lilly and Incyte’s Olumiant (baricitinib) Reports Additional Data Demonstrating Reduction in COVID-19 Recovery Time  Published: Oct 9, 2020 | Tags: COVID-19, Demonstrate, Incyte, Lilly, […]Read More

Santhera Halts P-III SIDEROS Study Evaluating Puldysa in Patients with

Shot:     Santhera has discontinued the development of Puldysa (idebenone) in patients with DMD who are in respiratory decline and receive concomitant glucocorticoid treatment. The DSMB has recommended the discontinuation of the SIDEROS study due to futility as it fails to meet its 1EPs i.e. the change of FVC%p from baseline to 18mos. of treatment Following […]Read More

PharmaShots Weekly Snapshot (Aug 31 – Sept 04, 2020)

1. AbbVie to License I-Mab’s Lemzoparlimab (TJC4) for ~$2B Published: Sept 04, 2020 | Tags: AbbVie, License, I-Mab, Lemzoparlimab, (TJC4), ~$2B 2. Kite and HiFiBiO Therapeutics Collaborate to Develop Antibodies Targeting Acute Myeloid Leukemia Published: Sept 03, 2020 | Tags: Kite, HiFiBiO Therapeutics, Collaborate, Antibodies, Targeting, Acute Myeloid Leukemia 3. Abbott Initiates LIFE-BTK Trial to […]Read More

Idorsia Transfers its Agreement with ReveraGen to Santhera for Vamorolone

Shots: Idorsia transfers its development & commercialization agreement with ReveraGen to Santhera, whereby Santhera shall replace Idorsia as a party to the agreement.  Santhera to get an exclusive license, including sublicensing rights, for vamorolone in all indications globally, including Japan and South Korea and a share in expected PR voucher In exchange for the revised […]Read More

Santhera Signs a Clinical Trial Agreement with Cold Spring Harbor

Shots: Santhera to provide its lonodelestat and intellectual support for the scientists at CSHL who will conduct the non-clinical research program and validates hNE as a target and shed light on lonodelestat as a potential therapy against COVID-19 Researchers at CSHL are part of the consortium of international non/clinical experts called the ‘NETwork to target […]Read More

PharmaShots Weekly Snapshot (November 18-22, 2019)

1.  Lupin Launches Smart Device for Metered-Dose Inhalers to Support Treatment of Respiratory Diseases in India Published: Nov 22, 2019 | Tags: Lupin, Launches, Smart Device, Metered-Dose Inhalers, Support, Treatment, Respiratory Diseases, India 2. BioMarin Reports Submission of MAA to EMA for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A Published: Nov 21, 2019 | Tags: BioMarin, […]Read More

Santhera Reports Results of Idebenone in SYROS Study for Duchenne

Shots: The SYROS study involves assessing of respiratory function evolution during periods of treatment with idebenone (900 mg/day) (On-Idebenone) compared to period without idebenone treatment (Off-Idebenone) in 18 patients with DMD not using glucocorticoids under Expanded Access Programs following P-III DELOS study, published in Neuromuscular Disorders The SYROS study results demonstrated long-term efficacy in slowing […]Read More

Santhera Signs an Exclusive License Agreement with Chiesi to Develop

Shots: Santhera to receive $49.5M upfront, ~$54.5M as milestones, making the total deal value ~104M. Chiesi to get an exclusive WW rights to develop & commercialize Raxone for LHON and other ophthalmological indications (Ex- the US & Canada) and has an option to fully acquire Santhera’s Raxone business The focus of the agreement is to […]Read More